SCHEMBL6489948

SCHEMBL6489948

[CH2]c1c(CC)c(C)nc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.52
MAPK1 P28482 1/20 0.47
ALDH1A1 P00352 5/20 0.47
CYP1A2 P05177 3/20 0.47
HPGD P15428 2/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 1/20 0.47
NUDT1 P36639 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
ADRA2A P08913 1/20 0.44
ADRA2C P18825 1/20 0.44
RXFP1 Q9HBX9 3/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPT P10636 1/20 0.44
CASP3 P42574 1/20 0.44
HTT P42858 2/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489952 0.83 GPR3 (0.53) GPR3MAPK1ALDH1A1CYP1A2HPGD
Ammonia Solution, Strong SCHEMBL29175740 0.83 GPR3 (0.53) GPR3MAPK1ALDH1A1CYP1A2HPGD
SCHEMBL7128183 0.80 CYP1A2 (0.62) GPR3MAPK1ALDH1A1CYP1A2HPGD
SCHEMBL6818967 0.80 GPR3 (0.50) GPR3MAPK1ALDH1A1CYP1A2HPGD
SCHEMBL10496106 0.79 GPR3 (0.53) GPR3MAPK1ALDH1A1CYP1A2HPGD
SCHEMBL3966414 0.79 GPR3 (0.57) GPR3MAPK1ALDH1A1CYP1A2HPGD
SCHEMBL16132377 0.77 GPR3 (0.47) GPR3MAPK1ALDH1A1CYP1A2HPGD
SCHEMBL14595374 0.76 PDE10A (0.66) KDM4EGAAHSD17B10SMN1; SMN2RXFP1
SCHEMBL3343183 0.76 KDM4E (0.69) GPR3ALDH1A1CYP1A2HPGDKDM4E
SCHEMBL6784629 0.76 ERN1 (0.57) GPR3MAPK1ALDH1A1CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962938-B2 Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-11-08 US disclosed
US-6720329-B2 ANTIINFLAMMATORY AGENTS BRISTOL-MYERS SQUIBB PHARMA 2004-04-13 US disclosed
EP-1373199-A4 SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) BRISTOL MYERS SQUIBB PHARMA CO (US) 2004-04-07 EP disclosed
EP-1373199-A2 SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) Bristol-Myers Squibb Pharma Company (US) 2004-01-02 EP disclosed
WO-2002074738-A2 SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) BRISTOL-MYERS SQUIBB COMPANY (US) 2002-09-26 WO disclosed